We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AtheroGenics Completes Enrollment in ANDES Trial
AtheroGenics Completes Enrollment in ANDES Trial
December 18, 2007
AtheroGenics has enrolled all patients in its trial of AGI-1067, a treatment for Type 2 diabetes.
The Phase III trial enrolled 999 patients in the U.S., South Africa, India and Eastern Europe.
AtheroGenics said it expects to announce final trial results in the second half of 2008.
